PHAXIAM Therapeutics (XPAR:PHXM) EBIT : €-3.32 Mil (TTM As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics EBIT?

PHAXIAM Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was €-5.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was €-3.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PHAXIAM Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 was -58.65%. PHAXIAM Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -566.24%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 75.49%.

PHAXIAM Therapeutics EBIT Historical Data

The historical data trend for PHAXIAM Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics EBIT Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-38.21

-62.17

-71.14

-51.66

0.61

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															14.66	-4.43	2.06	-	-5.38

Competitive Comparison of PHAXIAM Therapeutics's EBIT

For the Biotechnology subindustry, PHAXIAM Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's EV-to-EBIT falls into.

PHAXIAM Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.32 Mil.

PHAXIAM Therapeutics (XPAR:PHXM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PHAXIAM Therapeutics's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-23.028 * ( 1 - 0% )	/	( (39.265	+	0)	/ 1 )
=	-23.028	/	39.265
=	-58.65 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	65.531	-	12.734	-	( 25.189	-	max(0, 17.39	-	30.922	+	25.189	))
=	39.265

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

PHAXIAM Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-21.5	/	( ( (3.797 + max(-14.683, 0))	+	(0 + max(0, 0)) )	/	1 )
=	-21.5	/	( ( 3.797	+	0 )	/	1 )
=	-21.5	/	3.797
=	-566.24 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.245	+	0	+	1.634)	-	(12.734	+	0.42	+	3.408)
=	-14.683

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

PHAXIAM Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-3.32	/	-4.398
	=	75.49 %

PHAXIAM Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.